您的当前位置:首页 > 行业数据 > 格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂
图片属性
图片格式:PNG 图片大小:297KB 图片尺寸:1811*735
同报告图片
 / 4
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第1页
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
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第2页
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第3页
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第4页
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第5页
所属报告: 【国金证券】传统Pharma龙头加速创新转型,拓展全球布局-250922(46页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠